Witryna26 mar 2024 · Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential Nov 18. High number of new directors Nov 16. Price target decreased to US$21.17 Nov 06. Price target decreased to US$21.17 Witryna17 lis 2024 · NEW YORK, Nov. 17, 2024 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral …
Vital Therapies and Immunic Therapeutics Announce
Witryna11 kwi 2024 · The trading price of Immunic Inc. (NASDAQ:IMUX) closed lower on Monday, April 10, closing at $1.33, -4.32% lower than its previous close. In examining the 52-week price action we see that the stock hit a 52-week high of $12.22 and a 52-week low of $1.11. ... According a new report published by BloombergNEF on investment in … Witryna17 lis 2024 · November 17, 2024. NEW YORK, Nov. 17, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a … simple fee realty listings
Immunic Reports New Data From Phase 2 EMPhASIS Trial of …
Witryna4 sie 2024 · NEW YORK, Aug. 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX ), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating ... Witryna20 paź 2024 · NEW YORK, Oct. 20, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating ... Witryna5 kwi 2024 · NEW YORK, April 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small … rawhide the pursuit cast